AstraZeneca plc (AZN) Ordinary US$0.25
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
AstraZeneca cancer drug secures US approval
5 December 2024 08:48
(Sharecast News) - AstraZeneca drug Imfinzi has been approved for use in the US for patients with limited stage small cell lung cancer, the biopharmaceutical specialist confirmed on Thursday.
-
AstraZeneca appoints Iskra Reic as vice-president of intl unit
4 December 2024 14:00
(Sharecast News) - AstraZeneca said it had appointed AstraZeneca today announced the appointment of Iskra Reic as Executive Vice President (EVP), International with responsibility for overall strategy and...
-
AstraZeneca reports positive results from prostate cancer trial
25 November 2024 07:17
(Sharecast News) - AstraZeneca announced positive results from a phase three prostate cancer trial on Monday, reporting that its AKT inhibitor 'Truqap', or capivasertib, in combination with...
-
AstraZeneca's Tagrisso recommended for EU approval
18 November 2024 09:11
(Sharecast News) - Drugmaker AstraZeneca said on Monday that its Tagrisso asset had received a recommendation for EU approval on the back of LAURA Phase III trial results, which revealed it had extended...
-
Sunday newspaper round-up: Kursk, AstraZeneca, BAE Systems
17 November 2024 18:14
(Sharecast News) - America's President has authorised Ukraine to employ long-range ATACMS supplied by the US to strike targets inside Russia. More specifically, Kyiv will now be allowed to strike...
-
Director dealings: AstraZeneca CEO ups stake
15 November 2024 16:11
(Sharecast News) - AstraZeneca revealed on Friday that chief executive officer Pascal Soriot had acquired 20,000 ordinary shares in the FTSE 100-listed drugmaker.
-
London close: Stocks end turbulent week in the red
15 November 2024 15:21
(Sharecast News) - London stocks ended Friday in negative territory, weighed down by losses in pharmaceutical shares and a surprise slowdown in UK economic growth during the third quarter.
-
London close: Stocks sink as UK jobless rate rises
12 November 2024 16:39
(Sharecast News) - London stocks fell sharply on Tuesday as investors digested recent UK employment data alongside broader market reactions to Donald Trump's US presidential victory last week.
-
AstraZeneca upgrades full-year guidance amid strong momentum
12 November 2024 07:17
(Sharecast News) - AstraZeneca upgraded its full-year revenue and earnings per share guidance on Tuesday, citing strong growth across key therapy areas and robust financial results for the first nine months...
-
AstraZeneca "excited" by positive results in Tezspire clinical trial
8 November 2024 07:19
(Sharecast News) - AstraZeneca has announced positive high-level results from a phase III for its Texspire treatment for nasal polyps.
-
AstraZeneca says does not comment on media reports as shares slump
5 November 2024 17:18
(Sharecast News) - AstraZeneca said on Tuesday that it does not comment on speculative media reports, in response to a sharp drop in its share price.
-
AstraZeneca China president under investigation
30 October 2024 13:37
(Sharecast News) - Drugmaker AstraZeneca revealed on Wednesday that Leon Wang, the president of AstraZeneca China, was under investigation by Chinese authorities.
Company announcements Announcements
-
Directorate Change
16 December 2024 07:00
AstraZeneca
-
Imfinzi approved in US for limited-stage SCLC
5 December 2024 07:00
AstraZeneca
-
AstraZeneca appoints Iskra Reic EVP International
4 December 2024 13:45
AstraZeneca
-
Block listing Interim Review
2 December 2024 15:05
AstraZeneca
-
Total Voting Rights
2 December 2024 15:00
AstraZeneca
-
Truqap improved rPFS in advanced prostate cancer
25 November 2024 07:00
AstraZeneca
-
Director/PDMR Shareholding
20 November 2024 16:00
AstraZeneca
-
Tagrisso recommended for EU approval - LAURA
18 November 2024 07:00
AstraZeneca
-
Director/PDMR Shareholding
15 November 2024 10:00
AstraZeneca
-
Director/PDMR Shareholding
13 November 2024 16:00
AstraZeneca
-
AstraZeneca invests $3.5 billion in US
12 November 2024 07:10
AstraZeneca
-
KOMET Phase III trial met primary endpoint
12 November 2024 07:05
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.